Vascular disrupting effect of CKD-516: preclinical study using DCE-MRI Kyung Won KimJeong Min LeeByung Ihn Choi PRECLINICAL STUDIES 01 October 2013 Pages: 1097 - 1106
Role of IL-8 induced angiogenesis in uveal melanoma Laura LattanzioFederica TonissiCristiana Lo Nigro PRECLINICAL STUDIES 01 October 2013 Pages: 1107 - 1114
Digalloylresveratrol, a novel resveratrol analog inhibits the growth of human pancreatic cancer cells Philipp SaikoGeraldine GraserThomas Szekeres PRECLINICAL STUDIES 01 October 2013 Pages: 1115 - 1124
Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA Serena MarchettiDick PluimJan H. M. Schellens PRECLINICAL STUDIES 01 October 2013 Pages: 1125 - 1135
Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas Tina DasguptaDaphne A. Haas-KoganSue S. Yom PRECLINICAL STUDIES 01 October 2013 Pages: 1136 - 1141
Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer Ruud P. M. DingsJoseph I. LevineKevin H. Mayo PRECLINICAL STUDIES 01 October 2013 Pages: 1142 - 1150
Novel bourgeonal fragrance conjugates for the detection of prostate cancer Alexander SturzuSumbla SheikhStefan Heckl PRECLINICAL STUDIES 01 October 2013 Pages: 1151 - 1157
Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line Yohei FunakoshiToru MukoharaHironobu Minami PRECLINICAL STUDIES 01 October 2013 Pages: 1158 - 1168
Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner Panagiotis J. VlachostergiosEleana HatzidakiChristos N. Papandreou PRECLINICAL STUDIES 01 October 2013 Pages: 1169 - 1181
A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors Ivan Diaz-PadillaHal HirtePhilippe L. Bedard PHASE I STUDIES Open access 01 October 2013 Pages: 1182 - 1191
Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies Gerald S. FalchookSiqing FuRazelle Kurzrock PHASE I STUDIES 01 October 2013 Pages: 1192 - 1200
Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies Shaji K. KumarJames JettAlex A. Adjei PHASE I STUDIES 01 October 2013 Pages: 1201 - 1206
Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck Jean-Pascal MachielsMarie-Christine KaminskyJean-Pierre Delord PHASE I STUDIES 01 October 2013 Pages: 1207 - 1216
Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome Ivana GojoAlexander PerlEdward A. Sausville PHASE I STUDIES 01 October 2013 Pages: 1217 - 1227
An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer Joanne BradyPippa CorrieMohandas Mallath PHASE I STUDIES 01 October 2013 Pages: 1228 - 1235
Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors Cristiana SessaGianluca Del ConteLuca Gianni PHASE I STUDIES 01 October 2013 Pages: 1236 - 1243
A Phase I Study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer Balazs HalmosYuxia JiaAfshin Dowlati PHASE I STUDIES 01 October 2013 Pages: 1244 - 1250
Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies Erin SchenkAndrea E. Wahner HendricksonCharles Erlichman PHASE I STUDIES 01 October 2013 Pages: 1251 - 1256
A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer I. Garrido-LagunaK. A. McGregorS. Sharma PHASE I STUDIES 01 October 2013 Pages: 1257 - 1264
Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor Tetsuhide ItoTakuji OkusakaMasayuki Imamura PHASE II STUDIES Open access 01 October 2013 Pages: 1265 - 1274
Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer Isamu OkamotoKeisuke AoeTomohide Tamura PHASE II STUDIES 01 October 2013 Pages: 1275 - 1282
Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study Tim EisenYaroslav ShparykIgor Bondarenko PHASE II STUDIES 01 October 2013 Pages: 1283 - 1293
A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2 Yousuke NakaiHiroyuki IsayamaKazuhiko Koike PHASE II STUDIES 01 October 2013 Pages: 1294 - 1299
A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer K. H. ParkJ. H. SohnJ. H. Seo PHASE II STUDIES 01 October 2013 Pages: 1300 - 1306
A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109 Lida A. MinaMenggang YuRobin Zon PHASE II STUDIES Open access 01 October 2013 Pages: 1307 - 1310
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance) Pankaj GuptaFlora Mulkeyfor the Alliance for Clinical Trials in Oncology PHASE II STUDIES 01 October 2013 Pages: 1311 - 1320
Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer—CRAFT study Tohru TezukaChikuma HamadaKeiji Koda PHASE II STUDIES Open access 01 October 2013 Pages: 1321 - 1329
Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: Results of a Phase II trial Craig ReynoldsAlexander I. SpiraLina Asmar PHASE II STUDIES 01 October 2013 Pages: 1330 - 1338
Patupilone in patients with pretreated metastatic/locally recurrent colorectal cancer: results of the Phase II CINATRA trial S. Y. MoorcraftI. ChauC. Swanton PHASE II STUDIES 01 October 2013 Pages: 1339 - 1344
Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study David M. HyamsArlene ChanPaula Klein PHASE II STUDIES 01 October 2013 Pages: 1345 - 1354
In silico analysis of the amido phosphoribosyltransferase inhibition by PY873, PY899 and a derivative of isophthalic acid Sidra BatoolMuhammad Sulaman NawazMohammad A. Kamal SHORT REPORT 01 October 2013 Pages: 1355 - 1363
Bronchoscopic findings for bevacizumab-related pulmonary hemorrhage in advanced non–small cell lung cancer Kunio OkamotoIsamu OkamotoKazuhiko Nakagawa SHORT REPORT 01 October 2013 Pages: 1364 - 1366
Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors Changhoon YooMin-Hee RyuYoon-Koo Kang SHORT REPORT 01 October 2013 Pages: 1367 - 1374
The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer Mohamed A. KhalilWei QiaoDavid R. Fogelman SHORT REPORT 01 October 2013 Pages: 1375 - 1383
Bcl-2 antagonists: a proof of concept for CLL therapy Kumudha BalakrishnanVarsha Gandhi REVIEW 01 October 2013 Pages: 1384 - 1394
Erratum to: Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer Isamu OkamotoKeisuke AoeTomohide Tamura Erratum 01 October 2013 Pages: 1395 - 1396
Erratum to: Vascular disrupting effect of CKD-516: preclinical study using DCE-MRI Kyung Won KimJeong Min LeeByung Ihn Choi Erratum 01 October 2013 Pages: 1397 - 1397
